Prime time for immune-checkpoint targeted therapy at ASCO 2015

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Marabelle, Aurélien ^a,b   Routy, Bertrand ^a,b   Michels, Judith ^a,b   Kroemer, Guido ^a,c,d,e,f   Zitvogel, Laurence ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c Institut Gustave Roussy   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; VEMURAFENIB;

BILE DUCT CARCINOMA; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER STAGING; DRUG EFFICACY; ESOPHAGUS CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; METASTATIC MELANOMA; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SMALL CELL LUNG CANCER;

EID: 84961588772     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1068494     Document Type: Review

References (27)

1. A.Daud, A.Ribas, C.Robert, S.Hodi, J.D.Wolchok, A.M.Joshua, W.-J.Hwu, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015; 33 (suppl; abstr 9005); PMID:25605849; http://dx.doi.org/10.1200/JCO.2014.57.5027
2. D.R.Spigel, K.L.Reckamp, N.A.Rizvi, E.Poddubskaya, H.J.West, W.E.E.Eberhardt, P.Baas, S.J.Antonia, A.Pluzanski, E.E.Vokes, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs. docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl; abstr 8009); PMID:25897158
3. J.Brahmer, K.L.Reckamp, P.Baas, L.Crino, W.E.Eberhardt, E.Poddubskaya, S.Antonia, A.Pluzanski, E.E.Vokes, E.Holgado, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(2):123-35; PMID:26028407
4. L.Paz-Ares, L.Horn, H.Borghaei, D.R.Spigel, M.Steins, N.Ready, L.Chow, E.E.Vokes, E.Felip, E.Holgado, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl; abstr LBA109).
5. L.Horn, D.R.Spigel, S.Gettinger, S.Antonia, M.S.Gordon, R.S.Herbst, L.V.Sequist, C.Chappey, M.Kowanetz, A.Sandler, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J Clin Oncol 2015; 33 (suppl; abstr 8029); PMID:25897158
6. D.R.Spigel, K.L.Reckamp, S.Gettinger, B.Chao, L.Dirix, P.Schmid, L.Q.Chow, C.Chappey, M.Kowanetz, A.Sandler, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl; abstr 8028); PMID:25897158
7. T.Y.Seiwert, R.I.Haddad, S.Gupta, R.Mehra, M.Tahara, R.Berger, S.Lee, B.Burtness, D.T.Le, K.Heath, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 2015; 33 (suppl; abstr LBA6008); PMID:25667282
8. M.L.Disis, M.R.Patel, S.Pant, J.R.Infante, C.Lockhart, K.Kelly, J.T.Beck, M.S.Gordon, G.Weiss, S.Ejadi, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. J Clin Oncol 2015; 33 (suppl; abstr 5509); PMID:25918278
9. A.Varga, S.A.Piha-Paul, P.A.Ott, J.M.Mehnert, D.Berton-Rigaud, E.A.Johnson, J.D.Cheng, S.Yuan, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol 2015; 33 (suppl; abstr 5510).
10. P.A.Ott, M.E.E.Fernadez, S.Hiret, D.-W.Kim, R.A.Moss, T.Winser, S.Yuan, J.D.Cheng, B.Piperdi, M.Janice. Mehnert. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 2015; 33 (suppl; abstr 7502).
11. A.B.El-Khoueiry, I.Melero, T.S.Crocenzi, T.H.Welling, T.H.Yau, W.Yeo, A.Chopra, J.Grosso, L.Lang, J.Anderson, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33 (suppl; abstr LBA101).
12. D.Toshihikod, S.A.Piha-Paul, S.I.Jalal, H.Mai-Dang, S.Yuan, M.Koshiji, I.Csiki, J.Bennouna. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol 2015; 33 (suppl; abstr 4010).
13. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
14. M.S.Rooney, S.A.Shukla, C.J.Wu, G.Getz, N.Hacohen. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48-61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
15. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
16. D.T.Le, J.N.Uram, H.Wang, B.Bartlett, H.Kemberling, A.Eyring, A.Skora, N.S.Azad, N.A.Laheru, R.C.Donehower, et al. PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol 2015; 33 (suppl; abstr LBA100); http://dx.doi.org/10.1200/JCO.2014.57.4244
17. D.T.Le, J.N.Uram, H.Wang, B.R.Bartlett, H.Kemberling, A.D.Eyring, A.D.Skora, B.S.Luber, N.S.Azad, D.Laheru, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
18. S.V.Liu, J.D.Powderly, R.Camidge, N.Ready, R.S.Heist, F.S.Hodi, G.Giaccone, B.Liu, J.Wallin, R.P.Funke, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl; abstr 8030); http://dx.doi.org/10.1200/JCO.2014.57.7999
19. V.Papadimitrakopoulou, A.Patnaik, H.Borghaei, J.Stevenson, L.Gandhi, M.A.Gubens, J.C.H.Yang, L.V.Sequist, L.G.Ge, J.Bourque. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol 2015; 33 (suppl; abstr 8031).
20. A.Patnaik, M.A.Socinski, M.A.Gubens, L.Gandhi, J.Stevenson, R.D.Bachman, J.B.Bourque, J.Y.Ge, E.Im, S.M.Gadgeel. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol 2015; 33 (suppl; abstr 8011).
21. S.J.Antonia, M.H.Taylor, E.Calvo, D.Jaeger, F.G.De Braud, P.A.Ott, M.C.Pietanza, L.Horn, D.T.Le, M.Morse. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 2015; 33, 2015 (suppl; abstr 7503); PMID:25897158
22. I.Puzanov, M.M.Milhem, R.H.I.Andtbacka, D.R.Minor, O.Hamid, A.Li, J.Chou, H.Kaufman. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2015; 33 (suppl; abstr 9063); PMID:25800770
23. R.C.Bowen, S.Meek, M.Williams, K.F.Grossmann, R.Andtbacka, T.L.Bowles, J.R.Hyngstrom, S.A.Leachman, D.Grossman, S.L.Holmen, et al. A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. J Clin Oncol 33 (suppl; abstr 3018); PMID:25366685
24. A.N.Shoushtari, M.A.Postow, T.Z.Horvat, N.G.Adel, T.Dang, P.B.Chapman. Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events. J Clin Oncol 2015; 33 (suppl; abstr e20023).
25. P.Prithviraj, G.A.McArthur, V.Atkinson, P.Parente, M.C.Andrews, S.Parakh, J.S.Cebon, O.Klein. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. J Clin Oncol 2015; 33 (suppl; abstr 9059).
26. L.A.Kottschade, R.R.McWilliams, S.Markovic, M.S.Block, J.S.Bisneto, A.Q.Pham, R.S.Dronca. The use of pembrolizumab for the treatment of metastatic uveal melanoma. J Clin Oncol 2015; 33 (suppl; abstr 9010).
27. Z.Eroglu, D.W.Kim, D.B.Johnson, A.P.Algazi, P.R.Munhoz, E.Liniker, B.Kong, N.Khurana, B.Chmielowski, J.A.Sosman et al. Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. J Clin Oncol 2015; 33 (suppl; abstr 9011).